July 12, 2018

Quiknos raises almost RMB 100M in Series B led by NGP Capital to further enhance the primary medical service in China

Dive into the latest perspectives, insights,
and updates from our global community.

Written by:

No items found.
No items found.

Founded in 2015, Quiknos connects rural clinics to medical labs using its mobile platform and medical logistics system. They offer medical testing of blood, urine, liver function, Hepatitis B and more, which enable rural clinics and patients to access the best medical test service in China.

Quiknos’ businesses cover both digital health and smart mobility, which are two investment focus areas for NGP Capital. In the past years, NGP Capital has been actively investing behind opportunities in the 3rd and 4th tier rural areas of China.

David Tang, Managing Partner of NGP Capital stated, “Currently, only 11% of patients in rural areas have access to medical testing, and the inequality of medical resources need to be addressed. The market potential is huge and it is growing steadily. We believe Quiknos is able to provide quality medical treatment to more people in lower tier areas and we are happy to be part of the journey.”  

“We are delighted to see that since our Series A in 2017, Quiknos has quickly become the industry leader by geographical expansion and test items increase. Therefore, we decided to increase our investment to further empower the company’s development, which will benefit the whole primary health care market.“ Wu Kai, Partner of Softbank China stated.  

Charles Wang, Founder and CEO of Quiknos said, “We are happy to have the leading VCs working with us. During the past years we have been growing fast, and with the funds raised this round, we are able to expand our business making medical tests more accessible for mass population. We aim to enhance our service quality, develop new services for better user experiences. Our goal is to become the most trusted primary medical service platform in China.”  

About NGP Capital

NGP Capital is a globally engaged venture capital fund backing growth-stage and revenue-generating technology companies that will shape and power a fully connected world. By operating one, global fund with over $1.2 billion under management, we extend us our companies’ reach via on-the-ground teams in U.S., Europe, India and China making our portfolio company products and services local everywhere. www.ngpcap.com

About Softbank China

Established in 2000, Softbank China Venture Capital (SBCVC) is a leading venture capital and private equity firm that manages both USD and RMB funds. Its investment focuses on high-tech, high growth companies in TMT, clean technology, healthcare, consumer/retail, and advanced manufacturing sectors; and it invests across all stages of companies. SBCVC have a proven track record and solid reputation in identifying high potential start-ups and creating successful industry-leading companies. Some of their spotlight portfolio companies are Alibaba, Taobao, Focus Media, GDS, BGI, Ankon, Di’an, and Edan.  

About Quiknos

Established in May 2015, Quiknos is China’s leading service provider for primary healthcare institutions. Quiknos is the first to combine the service capabilities of mobile internet and medical cold chain logistics to serve primary healthcare sector in China’s rural areas. With the information and logistics systems support, Quiknos has made high quality clinical lab test service accessible to patients even in remote villages, enabling doctors in public health centers or private clinics to make more accurate diagnoses. By empowering primary healthcare institutions, Quiknos promotes the effective distribution of medical resources, making quality medical services at the fingertips, wherever the patients are. Today, Quiknos covers a vast service area in Fujian, Guangdong, Sichuan, Chongqing, Zhejiang, Hunan, Jiangxi, etc., and has reached business cooperation with nearly 20,000 primary healthcare institutions, serving thousands of people on a daily basis.